

**Please type a plus sign (+) inside this box**

**SUBSTITUTE for PTO/SO/08A (08-00)** Approved for use through 10/31/2002. OMB 0651-0031  
Information Disclosure Statement by Applicant  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO  
**INFORMATION DISCLOSURE**  
**STATEMENT BY APPLICANT**

COMPLETE IF KNOWN	
Application Number	10/020,746
Filing Date	December 14, 2001
First Named Inventor	R.K. Bakshi et al.
Group Art Unit	To Be Assigned 1624
Examiner Name	To Be Assigned Coleman
Attorney Docket Number	19526PR

#### **OTHER NON PATENT LITERATURE DOCUMENTS**

Examiner Signature	Brenda Coleman	Date Considered	Nov. 21, 2003
--------------------	----------------	-----------------	---------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.  
Draw line through citation if not in conformance and not considered.

Please type a plus sign (+) inside this box

Approved for use through 10/31/2002. OMB 0651-0031  
SUBSTITUTE for PTO/SO-08A (08-00). Information Disclosure Statement by Applicant  
Part of Trademark Office, U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

*(use as many sheets as necessary)*

**COMMA IF KNOWN**

10/020, 740

December 14, 2001

Bakshi, R.K. et al.

~~To Be Assigned~~ 1624

~~To Be Assigned~~ Coleman

She

2

01

6

**Attorney Docket Number**

## **FOREIGN PATENT DOCUMENTS**

**Examiner  
Signature**

Brenda Coleman

**Date Considered**

Nov. 21, 2003

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

**Draw line through citation if not in conformance and not considered.**

Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box

Approved for use through 10/31/2002. OMB 0651-0031  
SUBSTITUTE for PTO FORM 98A (08-00). Information Disclosure Statement by Applicant  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

<p>Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i></p>		<b>COMBINE IF KNOWN</b>	
		Application Number	10/020,740
		Filing Date	December 14, 2001
		First Named Inventor	R.K. Bakshi et al.
		Group Art Unit	To Be Assigned 1624
		Examiner Name	To Be Assigned Coleman
Sheet	3	of	4
		Attorney Docket Number 19526PR	

OTHER NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	AA	Bakshi et al., 4-aza-3-oxo-5a-androst-1-ene-17b-N-aryl-carboxamides as dual inhibitors of human type 1 and 2 steroid 5a-reductases. J. Med. Chem. 38 (1995), pp. 3189-3192 <i>duplicate</i>
BC	AB	Andriole et al., "Treatment with Finasteride Following Radical Prostatectomy for Prostate Cancer", Urology 45(3): 491-497 (1995)
BC	AC	Tsukamoto et al., "Chemoprevention of Rat Prostate Carcinogenesis by Use of Finasteride or Casodex", 87 J. Natl Cancer Inst., pp. 842-843 (1995)
BC	AD	Tolman et al., 5th Int'l Congress Hormones & Cancer Program and Abstract, Quebec City, Sept. 16-20, 1995, p.92, Abstract 48, "4-methyl-4-azasteroid 17beta(N-aryl substituted)carboxamides: Potent antiandrogenic activity with 5a-reductase inhibition"
BC	AE	Tolman et al., "4-Methyl-3-oxo-4-aza-5alpha-androst-1-en17beta-N-aryl-carboxamide: An approach to combined androgen blockade"; in press, expected to publish in March 1996 issue of J. Steroid Biochem & Molec. Bio
BC	AF	Bologna et al, "Antiandrogens and 5-alpha Reductase Inhibition of the Proliferation Rate in PC3 and DU145 Human Prostatic Cancer Cell Lines", 51(6) Curr. Ther. Res., pp. 799-813 (1992)
BC	AG	Denis, Commentary on maximal androgen blockade in prostate cancer: A theory to put into practice. Prostate 27 (1995), pp. 223-240
BC	AH	Bakshi et al., ACS Division of Medicinal Chemistry, 209th ACS Nat'l meeting Anaheim, CA, April 2-6, 1995, Abstract No. 011, "N-Phenyl-3-oxo-4-aza-5alpha-androst-1-en-17beta-carboxamides as inhibitors of both human type 1 and type 2 5alpha-redutases
BC	AI	Rasmussen et al., J. Med. Chem., Vol. 29, pp. 2298-2315 (1986), "Azasteroids: Structure-activity relationships for inhibition of 5alpha-reductase and of androgen receptor binding."
BC	AJ	Liang et al., Endocrinology, Vol. 117, pp. 571-579 (1985), "Species differences in prostatic steroid 5alpha-reductases of rat, dog, and human"
BC	AK	Bakshi, R.K., et al., "4-Aza-3-oxo-5a-androst-1-ene-17b-N-aryl-carboxamides as Dual Inhibitors of Human Type 1 and Type 2 Steroid 5a-Reductases. Dramatic Effect of N-Aryl Substituents on Type 1 and Type 2 5a-Reductase Inhibitory Potency.", J. Med. Chem., Vol. 38, No. 17, 1995
BC	AL	Bakshi, et al., Additions and Corrections, J. of Med. Chem., Vol. 39, No. 5, p. 1192, 1996
BC	AM	Mellin, T.N., et al., "Azasteroids as Inhibitors of Testosterone 5a-Reductase In Mammalian Skin", J. of Steroid Biochem. and Molec. Bio., Vol. 44, No. 2, pp. 121-131, 1993
BC	AN	Rasmussen, G.H., et al., "Azasteroids as Inhibitors of Rat Prostatic 5a-Reductase", J. of Med. Chem., Vol. 27, No. 12, pp. 1690-1701, 1984
BC	AO	Zheng, Jinhong, et al., Chem. Abs., Vol. 122, No. 25, 1995

Examiner Signature	Brenda Coleman	Date Considered	Nov. 21, 2003
--------------------	----------------	-----------------	---------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.  
Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box

Approved for use through 10/31/2002. OMB 0651-0031  
**SUBSTITUTE for PTO Form 1A (08-00), Information Disclosure Statement by Applicant**  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

*(use as many sheets as necessary)*

Sheet **1** of **4** Attorney Docket Number

10/020, 740 #4

**Application Number:** 10/020

**Filing Date** December 14, 2001

**First Named Inventor** R.K. Bakshi et al.

Group Art Unit ~~To Be Assigned~~ 1624

Examiner Name To Be Assigned Coleman 9/20/00

101

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number		
BC		PCT	WO 91/07861	Merck & Co., Inc.	04/14/1994
BC		PCT	WO 92/16213	Merck & Co., Inc.	10/01/1992
BC		EPO	0 484 094	Sankyo Company Limited	06/05/1992
BC		PCT	WO 95/07926	Glaxo Inc.	03/25/1995
BC		EPO	0 538 192	CIBA-GEIGY AG	04/21/1993
BC		PC T	WO 95/07927	Glaxo Inc.	03/23/2001
BC		PCT	WO 97/11702	Merck & Co., Inc.	04/03/1997
BC		PCT	WO 94/15602	Merck & Co., Inc.	07/21/1994
BC		PCT	WO 94/11385	Smith-Kline Beecham Corporation	05/26/1994
BC		EPO	0 004 949 A1	Merck & Co., Inc.	04/12/1979

**\*\* structures only**

**Examiner  
Signature**

Brenda Coleman

**Date Considered**

Nov. 21, 2003

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

**Draw line through citation if not in conformance and not considered.**

**Include copy of this form with next communication to applicant.**